No Elevated Cancer Risk for RA Patients With Tocilizumab (CME/CE)
(MedPage Today) -- Combined risk for new cancers except non-melanoma skin cancer with IL-6r inhibitor not significantly different than with TNF inhibitors (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 20, 2019 Category: Hematology Source Type: news

No Rise in Cancer Risk for RA Patients on Actemra
(MedPage Today) -- Similar to malignancy risk with TNF inhibitors and abatacept (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 14, 2019 Category: Primary Care Source Type: news

IL-6 Blockade Aids Quality of Life in Vasculitis
(MedPage Today) -- Findings were'unprecedented'with tocilizumab in giant cell arteritis (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 27, 2019 Category: Primary Care Source Type: news

RA Biologics Carry SimilarInfection Risk (CME/CE)
(MedPage Today) -- Risks of serious bacterial infections, skin and soft tissue infections, higher with tocilizumab (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - February 6, 2019 Category: Infectious Diseases Source Type: news

RA Biologics Carry Similar Infection Risk (CME/CE)
(MedPage Today) -- Risks of serious bacterial infections, skin and soft tissue infections, higher with tocilizumab (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - February 6, 2019 Category: Infectious Diseases Source Type: news

Infection Risks Similar for Biologics in RA
(MedPage Today) -- Certain infections more common with tocilizumab, large study finds (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - February 1, 2019 Category: Infectious Diseases Source Type: news

IL-1 Blocker Succeeds in Real-World Vasculitis
(MedPage Today) -- Clinical and laboratory improvements seen with tocilizumab in refractory giant cell arteritis (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 13, 2019 Category: Primary Care Source Type: news

IL-6 Blocker Succeeds in Real-World Vasculitis
(MedPage Today) -- Clinical and laboratory improvements seen with tocilizumab in refractory giant cell arteritis (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 13, 2019 Category: Primary Care Source Type: news

Exercise Can Shrink Belly Fat, But Not When Drug Blocks IL-6 Exercise Can Shrink Belly Fat, But Not When Drug Blocks IL-6
Exercise reduced abdominal visceral fat, a risk factor for cardiometabolic disease, but not when obese patients received tocilizumab, an anti-arthritis drug that blocks IL-6 receptors, in a new study.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 27, 2018 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

FDA approves Genentech ’s prefilled autoinjector for Actemra
Roche‘s (OTC:RHHBY) Genentech said today that the FDA approved its ACTPen single-dose prefilled autoinjector for Actemra as a new formulation for adults with moderate to severe active rheumatoid arthritis and for adults with giant cell arteritis. The U.S. regulatory agency also approved the device for administration by caregivers to patients as young as two years old with active polyarticular juvenile idiopathic arthritis or active systemic juvenile idiopathic arthritis. Get the full story at our sister site, Drug Delivery Business News.   The post FDA approves Genentech’s prefilled autoinjector ...
Source: Mass Device - November 26, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Wall Street Beat Genentech Source Type: news

FDA approves the ACTPen for Roche ’s Actemra, a single-dose, prefilled autoinjector for the treatment of rheumatoid arthritis, giant cell arteritis and two forms of juvenile arthritis
Roche announced today that the US Food and Drug Administration (FDA) has approved ACTPen ™ 162 mg/0.9 mL, a single-dose prefilled autoinjector for Actemra®(tocilizumab) as an additional formulation for adult patients with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs), and for adul t patients with giant cell arteritis (GCA). (Source: Roche Investor Update)
Source: Roche Investor Update - November 26, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves The ACTpen for Actemra, A Single-Dose, Prefilled Autoinjector
South San Francisco, CA -- November 26, 2018 -- Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved ACTPen™ 162 mg/0.9 mL, a single-dose prefilled autoinjector for Actemra... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 26, 2018 Category: Drugs & Pharmacology Source Type: news

Tocilizumab and Work/Housework Status in Biologic-Naive RA Tocilizumab and Work/Housework Status in Biologic-Naive RA
In what ways might treatment with subcutaneous tocilizumab impact activities of daily living and work productivity among patients with rheumatoid arthritis?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 27, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

CHMP recommends EU approval for subcutaneous formulation of RoActemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis
Roche announced today that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the subcutaneous (SC) formulation of RoActemra ® (tocilizumab) for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients one year of age and older. (Source: Roche Investor Update)
Source: Roche Investor Update - September 21, 2018 Category: Pharmaceuticals Source Type: news

Genentech wins FDA nod for subcutaneous formulation of arthritis drug
Roche‘s (OTC:RHHBY) Genentech reported this week that the FDA approved the subcutaneous formulation of tocilizumab for the treatment of active systemic juvenile idiopathic arthritis in patients two years and older. The U.S. agency approved the intravenous formulation of Actemra for the same indication in 2011. Get the full story at our sister site, Drug Delivery Business News.   The post Genentech wins FDA nod for subcutaneous formulation of arthritis drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 14, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Featured Food & Drug Administration (FDA) Orthopedics Pharmaceuticals Regulatory/Compliance Wall Street Beat Genentech Source Type: news

FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA)
South San Francisco, CA -- September 13, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 14, 2018 Category: Drugs & Pharmacology Source Type: news

FDA approves subcutaneous formulation of Actemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis
Roche announced today that the US Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra ® (tocilizumab) for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients two years of age and older. (Source: Roche Investor Update)
Source: Roche Investor Update - September 13, 2018 Category: Pharmaceuticals Source Type: news

No Increased CVD Risk With IL-6 Blocker in RA (CME/CE)
(MedPage Today) -- Concerns had been raised because of elevated lipids with tocilizumab use (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 5, 2018 Category: Cardiology Source Type: news

Accelerated Subcutaneous Nodulosis in Tocilizumab-Treated RA Accelerated Subcutaneous Nodulosis in Tocilizumab-Treated RA
This report details new and worsening subcutaneous nodulosis in a case series of patients with rheumatoid arthritis treated with the monoclonal antibody tocilizumab.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 15, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

New jab to help patients at risk of going blind from common condition
Tocilizumab, a drug that targets a chemical responsible for inflammation, could help countless people with giant cell arteritis (GCA). (Source: the Mail online | Health)
Source: the Mail online | Health - July 9, 2018 Category: Consumer Health News Source Type: news

Roche ’s RoActemra gains positive CHMP opinion for CAR T-cell-induced cytokine release syndrome
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of RoActemra ® (tocilizumab) for the treatment of cytokine release syndrome (CRS), in adults and pediatric patients aged two years and older. (Source: Roche Investor Update)
Source: Roche Investor Update - June 29, 2018 Category: Pharmaceuticals Source Type: news

Meds Improve Cardiovascular Risk in RA
(MedPage Today) -- Benefits seen for hydroxychloroquine, methotrexate, and tocilizumab (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 15, 2018 Category: Cardiology Source Type: news

No difference in malignancy rates seen between tocilizumab and TNFi in patients with RA
(European League Against Rheumatism) The results of a study presented at the Annual European Congress of Rheumatology (EULAR 2018) examined rates of malignancy in patients with rheumatoid arthritis (RA), excluding non-melanoma skin cancer (NMSC), and found no difference between those newly treated with tocilizumab (TCZ) versus TNF inhibitors (TNFi). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 15, 2018 Category: Cancer & Oncology Source Type: news

Safe Stopping of Tocilizumab in RA: MTX Helps Safe Stopping of Tocilizumab in RA: MTX Helps
Patients with rheumatoid arthritis who achieve 6 months of remission or low disease activity by taking methotrexate plus tocilizumab can usually stop tocilizumab; restarting is effective if flares occur.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 13, 2018 Category: Consumer Health News Tags: Rheumatology News Source Type: news

FDA approves subcutaneous formulation of Actemra for use in active polyarticular juvenile idiopathic arthritis (pJIA), a rare form of juvenile arthritis
Roche announced today that the US Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra ® (tocilizumab) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older. (Source: Roche Investor Update)
Source: Roche Investor Update - May 15, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Subcutaneous Formulation of Actemra for use in Active Polyarticular Juvenile Idiopathic Arthritis
South San Francisco, CA -- May 14, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra ®... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 14, 2018 Category: Drugs & Pharmacology Source Type: news

Tocilizumab Beats Anti-TNFs for Treatment Retention
(MedPage Today) -- Longer time on treatment, regardless of additional DMARDs (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - May 8, 2018 Category: Rheumatology Source Type: news

High CV Risk Not Seen for Tocilizumab (CME/CE)
(MedPage Today) -- Despite elevated lipids seen with the IL-6 blocker (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 4, 2018 Category: Cardiology Source Type: news

Biologics Differ in Safety Risks (CME/CE)
(MedPage Today) -- Infection risks higher for tocilizumab (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 2, 2018 Category: Primary Care Source Type: news

Cipla's U-turn: Happily ever after?
In a foes-turn-friends move announced on February 27, the Mumbai-based drug maker announced that it will partner Swiss biotech company Roche to promote Actemra and Syndyma. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 1, 2018 Category: Pharmaceuticals Source Type: news

Cipla ties up with Roche to sell 2 cancer drugs in India
The pharma major will distribute Tocilizumab and Syndyma -- the second brand of Roche's cancer therapy bevacizumab -- in India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 27, 2018 Category: Pharmaceuticals Source Type: news

Etanercept, Tocilizumab and Interleukin-1 Inhibitors in JIA Etanercept, Tocilizumab and Interleukin-1 Inhibitors in JIA
What do we currently know about the efficacy and safety of these biologic agents in the treatment of systemic onset juvenile idiopathic arthritis?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 16, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Tocilizumab a'First Choice'  for PHID Syndrome Tocilizumab a'First Choice'  for PHID Syndrome
Tocilizumab should be the “ first choice ” for treatment of the autoinflammatory and cutaneous manifestations of pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) syndrome, say clinicians from the United Kingdom.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 30, 2017 Category: Consumer Health News Tags: Pediatrics News Source Type: news

Tocilizumab Benefits Persist in SSc (CME/CE)
(MedPage Today) -- Clinically meaningful results, but not statistically significant (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 25, 2017 Category: Primary Care Source Type: news

Godly gift for arthritis pain
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year. In 2015, the FDA asked drug makers to strengthen their warning labels. Since then, most have listed their dangerous side effects on the bottle. But one manufacturer thought they didn’t have to warn people about their dangerous drug. They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1 The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche....
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

RA Outcomes with Tocilizumab Surpass Those of Adalimumab, Methotrexate (CME/CE)
(MedPage Today) -- Benefits reflected in both physical and mental scores (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - September 25, 2017 Category: Rheumatology Source Type: news

European Commission approves Roche ’s tocilizumab to treat giant cell arteritis
Roche ’s Actemra / RoActemra (tocilizumab) has received approval from the European Commission (EC) to treat giant cell arteritis (GCA). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 25, 2017 Category: Pharmaceuticals Source Type: news

Roche receives EU approval for Gazyvaro, European approval for Actemra
ZURICH (Reuters) - Roche said it has received European approval for its Actemra medication in giant cell arteritis (GCA), the Swiss drugmaker said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - September 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Roche receives European approval for Actemra /RoActemra in giant cell arteritis
Roche announced today that the European Commission (EC) has approved Actemra ®/RoActemra® (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition. Actemra/RoActemra is the first therapy approved for the treatment of GCA in Europe. (Source: Roche Media News)
Source: Roche Media News - September 22, 2017 Category: Pharmaceuticals Source Type: news

Roche receives European approval for Actemra /RoActemra in giant cell arteritis
Roche announced today that the European Commission (EC) has approved Actemra ®/RoActemra® (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition. Actemra/RoActemra is the first therapy approved for the treatment of GCA in Europe. (Source: Roche Investor Update)
Source: Roche Investor Update - September 22, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Genentech ’s Actemra (tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
South San Francisco, CA -- August 30, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra ® (tocilizumab) intravenous injection for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 31, 2017 Category: Drugs & Pharmacology Source Type: news

FDA approves Roche ’s Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome
Roche announced today that the US Food and Drug Administration (FDA) has approved Actemra/RoActemra ® (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in patients two years of age and older. (Source: Roche Media News)
Source: Roche Media News - August 30, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome
Roche announced today that the US Food and Drug Administration (FDA) has approved Actemra/RoActemra ® (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in patients two years of age and older. (Source: Roche Investor Update)
Source: Roche Investor Update - August 30, 2017 Category: Pharmaceuticals Source Type: news

Tocilizumab Boosts Hemoglobin, Hematocrit in RA (CME/CE)
(MedPage Today) -- Significant increases for anemic RA patients at 6 and 24 months (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - August 12, 2017 Category: Geriatrics Source Type: news

Tocilizumab May Be Option in Giant Cell Arteritis (CME/CE)
(MedPage Today) -- Biologic agent with steroid taper performed better than steroids alone (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - August 11, 2017 Category: Consumer Health News Source Type: news

Genentech ’s Actemra meets primary and secondary endpoints in Phase III trial for GCA
Genentech has reported positive results from the Phase III GiACTA clinical trial of Actemra (tocilizumab) to treat adults with giant cell arteritis (GCA). (Source: Drug Development Technology)
Source: Drug Development Technology - July 28, 2017 Category: Pharmaceuticals Source Type: news

Tocilizumab With Steroid Taper Superior in GCA Tocilizumab With Steroid Taper Superior in GCA
Tocilizumab plus a 26-week prednisone taper was superior to either a short or long course of tapered prednisone treatment plus placebo in patients with giant cell arteritis, a study has found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 27, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Drug Beats Steroids for Controlling Blood Vessel Inflammation in Study
With tocilizumab's approval, there's an alternative treatment for giant cell arteritis Source: HealthDay Related MedlinePlus Pages: Giant Cell Arteritis, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - July 27, 2017 Category: Consumer Health News Source Type: news

Your NEJM Group Today: Rejecting Science, Harming Women / Tocilizumab for Giant-Cell Arteritis / NJ Primary Care Opportunities (FREE)
By the Editors Take a look at today's offering from NEJM Group:NEJM Audio Interview: Rejecting Science, Harming … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 27, 2017 Category: Primary Care Source Type: news